Relmada Therapeutics, Inc. RLMD
4.36 USD +0.09 (+1.99%)
Nov 4, 2026, 9:51 AM EST
4.33 Day range 4.60
2.42 52-week range 8.00
- YTD
- -9.83%
- 1 year
- +57.22%
- Market cap
- 465.08M
- EPS (ttm)
- -0.91
- Shares out
- 30.17M
- Forward P/E
- -0.19
- YTD return
- -9.83%
- 1-year return
- +57.22%
- Volume
- 394.03K
- Avg volume
- 1.36M
- Open
- 4.34
- Previous close
- 4.27
- Day's range
- 4.33 – 4.60
- 52-week range
- 2.42 – 8.00
- Beta
- 0.41
- Price target
- 0.86667 (-80.1%)
2Y +1.01 (+29.53%)
Key statistics
- Enterprise value
- 27.93M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -18.51M
- Total cash
- 70.44M
- Total debt
- 0
- Return on equity
- -100.41%
- Short % of float
- 4.23%
- 50-day average
- 2.53
- 200-day average
- 3.33
Analyst view
Price target (mean) 0.86667 -80.1% downside
Now 4.36
- Target (low)
- 0.60
- Target (mean)
- 0.86667
- Target (high)
- 1.00
Ratings (0m) 3 0 buy · 3 hold · 0 sell
- Strong buy0
- Buy0
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
RLMD Revenue — quarterly 0
RLMD Net income — quarterly -12.91M
RLMD EPS — quarterly -0.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.65 | -0.72 | -0.07 | -10.77% |
| Aug 7, 2024 | Jun 1, 2024 | -0.83 | -0.59 | +0.24 | +28.92% |
| May 8, 2024 | Mar 1, 2024 | -0.90 | -0.72 | +0.18 | +20.00% |
| Mar 19, 2024 | Dec 1, 2023 | -0.88 | -0.84 | +0.04 | +4.55% |
| Nov 8, 2023 | Sep 1, 2023 | -0.95 | -0.73 | +0.22 | +23.16% |
| Aug 8, 2023 | Jun 1, 2023 | -0.92 | -0.84 | +0.08 | +8.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Mizuho | down | Outperform | Neutral |
| Dec 4, 2024 | Leerink Partners | down | Outperform | Market Perform |
| Jun 5, 2024 | Goldman Sachs | down | Neutral | Sell |
| Jun 15, 2023 | Mizuho | reit | Buy | Buy |
| Jan 23, 2023 | SVB Leerink | main | — | Outperform |
| Oct 14, 2022 | Goldman Sachs | down | Buy | Neutral |
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- relmada.com
News
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026 
Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call 
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On 
12 Health Care Stocks Moving In Tuesday's After-Market Session - 12 Health Care Stocks Moving In Friday's Pre-Market Session
Relmada Therapeutics Q2 EPS $(0.11) Beats $(0.20) Estimate 
Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index 
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call 
This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday 
HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12
Your note
Sign in to keep a note on RLMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASAMENTO CHARLES J | Director | Stock Gift | Oct 21, 2024 | 0 |
| ENCE CHARLES | Officer | Purchase | Jan 30, 2024 | 38,970 |
| KELLY PAUL EDWARD | Director | Purchase | Sep 8, 2024 | 212,295 |
| O'GORMAN CEDRIC | Officer | Purchase | May 22, 2023 | 10,121 |
| SHENOUDA MAGED R | Chief Financial Officer | Purchase | Sep 10, 2024 | 88,335 |
| TRAVERSA SERGIO | Chief Executive Officer | Purchase | Sep 10, 2024 | 384,024 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Resources, Inc. | 13.16% | 1,302,151 | 494.30K | Sep 29, 2024 |
| Vanguard Group Inc | 12.70% | 1,256,705 | 477.05K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 11.99% | 1,186,452 | 450.38K | Sep 29, 2024 |
| Parsons Capital Management, Inc. | 10.13% | 1,002,695 | 380.62K | Sep 29, 2024 |
| Palo Alto Investors Lp | 7.40% | 732,400 | 278.02K | Sep 29, 2024 |
| Deep Track Capital, Lp | 6.82% | 674,833 | 256.17K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 8.61% | 851,916 | 323.39K | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 3.78% | 374,029 | 141.98K | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 3.57% | 353,625 | 134.24K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 1.59% | 157,021 | 59.60K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 1.01% | 100,177 | 38.03K | Sep 29, 2024 |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.94% | 93,077 | 35.33K | Oct 30, 2024 |